Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Variation in Quality an Important Issue for Future Biosimilars: Seminar
July 25, 2011
- Speakers at CPhI Japan 2011 Agree on Prospects for Growth in Vaccine Market
July 25, 2011
- 12 APIs Including Lixiana Added to NHI Price List
July 25, 2011
- PFSB Taking Public Comments on Revision of GLs for Equivalence Testing of Generic Drugs
July 25, 2011
- Pharmacy, Drugstore Industries Intensifying Efforts to Ensure Compliance with Regulations
July 25, 2011
- Korosho to Improve List of Accredited Foreign Drug Manufacturers
July 25, 2011
- Generics Account for 23.5% of Total Number of Drugs in 2010: Korosho Survey
July 25, 2011
- Psychiatric Disease to Be Added to 4 Designated Diseases in Healthcare Planning System
July 25, 2011
- Infrastructure Needed to Promote Orphan Drug Development: Health Minister Hosokawa
July 25, 2011
- Rate of Generic Drug Use Declined in February, March: Survey
July 25, 2011
- Korosho to Promote Anti-HTLV-1 Measures
July 25, 2011
- GSK Obtains Marketing Approval for Rotarix
July 18, 2011
- Taisei Kako Co-develops New Prefilled Syringe with Suzuken
July 18, 2011
- Kyowa Kirin to Enforce Safe Driver Education for New MRs
July 18, 2011
- 3 Products Including 4-Valent HPV Vaccine Gardasil Approved: MSD
July 18, 2011
- Nippon Kayaku Takes over Manufacturing Approval for Gelpart from Astellas
July 18, 2011
- Korosho to Announce Stance on Copayments for OTC-like Drugs by Year-end
July 18, 2011
- Takeda Obtains Approval for Liovel Combination Tab
July 18, 2011
- Korosho Panel Fails to Form Consensus on HbA1c Data Reporting
July 18, 2011
- Onbrez Approved for COPD: Novartis
July 18, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…